BR112021024001A2 - Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma - Google Patents
Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesmaInfo
- Publication number
- BR112021024001A2 BR112021024001A2 BR112021024001A BR112021024001A BR112021024001A2 BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2 BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A BR112021024001 A BR 112021024001A BR 112021024001 A2 BR112021024001 A2 BR 112021024001A2
- Authority
- BR
- Brazil
- Prior art keywords
- lysozyme
- methods
- treatment
- broad spectrum
- infections
- Prior art date
Links
- 102000016943 Muramidase Human genes 0.000 title abstract 6
- 108010014251 Muramidase Proteins 0.000 title abstract 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title abstract 6
- 229960000274 lysozyme Drugs 0.000 title abstract 6
- 235000010335 lysozyme Nutrition 0.000 title abstract 6
- 239000004325 lysozyme Substances 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002828 effect on organs or tissue Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853215P | 2019-05-28 | 2019-05-28 | |
| PCT/IB2020/055083 WO2020240472A1 (en) | 2019-05-28 | 2020-05-28 | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024001A2 true BR112021024001A2 (pt) | 2022-01-25 |
Family
ID=73551002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024001A BR112021024001A2 (pt) | 2019-05-28 | 2020-05-28 | Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200376094A1 (enExample) |
| EP (1) | EP3976093A4 (enExample) |
| JP (3) | JP7768769B2 (enExample) |
| CN (1) | CN114126643A (enExample) |
| AR (1) | AR119031A1 (enExample) |
| BR (1) | BR112021024001A2 (enExample) |
| CA (1) | CA3145530A1 (enExample) |
| CO (1) | CO2021017958A2 (enExample) |
| IL (1) | IL288531A (enExample) |
| MX (1) | MX2021014634A (enExample) |
| TW (1) | TW202110474A (enExample) |
| WO (1) | WO2020240472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112805027B (zh) * | 2020-04-27 | 2023-10-10 | 广州新创忆药物临床研究有限公司 | 一种抗新冠病毒感染的药物与应用 |
| WO2021217702A1 (zh) * | 2020-04-27 | 2021-11-04 | 广州新创忆药物临床研究有限公司 | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 |
| WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
| CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| PT1755576E (pt) * | 2004-04-08 | 2011-10-19 | Dermcare Vet Pty Ltd | Composições antimicrobianas e métodos para a sua utilização |
| CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
| US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| US8097434B2 (en) * | 2007-10-19 | 2012-01-17 | Becton, Dickinson And Company | Methods for the detection of beta-lactamases |
| CN102223876A (zh) * | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CN111973484A (zh) * | 2013-03-12 | 2020-11-24 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
| JP7055814B2 (ja) * | 2017-02-28 | 2022-04-18 | プリシジョンバイオティクス・グループ・リミテッド | 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム |
| US20200215169A1 (en) * | 2017-07-17 | 2020-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibacterial methods and related kits |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
-
2020
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en not_active Ceased
- 2020-05-28 JP JP2021571513A patent/JP7768769B2/ja active Active
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en not_active Withdrawn
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215483A patent/JP2025038034A/ja active Pending
-
2025
- 2025-10-30 JP JP2025183379A patent/JP2026021451A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126643A (zh) | 2022-03-01 |
| US20200376094A1 (en) | 2020-12-03 |
| TW202110474A (zh) | 2021-03-16 |
| WO2020240472A1 (en) | 2020-12-03 |
| CO2021017958A2 (es) | 2022-01-17 |
| EP3976093A4 (en) | 2023-07-05 |
| AR119031A1 (es) | 2021-11-17 |
| CA3145530A1 (en) | 2020-12-03 |
| US20240066105A1 (en) | 2024-02-29 |
| EP3976093A1 (en) | 2022-04-06 |
| JP2026021451A (ja) | 2026-02-10 |
| JP2025038034A (ja) | 2025-03-18 |
| IL288531A (en) | 2022-01-01 |
| JP7768769B2 (ja) | 2025-11-12 |
| MX2021014634A (es) | 2022-07-04 |
| US20220362354A1 (en) | 2022-11-17 |
| JP2022534776A (ja) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024001A2 (pt) | Formulações farmacêuticas antibacterianas de grande espectro compreendendo lisozima e métodos de uso da mesma | |
| ES2828711T3 (es) | Formulaciones de peróxido y métodos y aplicadores para usar las mismas | |
| JP2020527134A5 (enExample) | ||
| BR112022017891A2 (pt) | Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante | |
| CN108853312B (zh) | 聚桂醇外用凝胶及其制备方法 | |
| BR0013222A (pt) | Medicamento para aplicação tópica, uso de um xanteno halogenado, composição farmacêutica para administração tópica, e, método de tratamento | |
| CL2024002764A1 (es) | Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib | |
| BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
| AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| BR0314617A (pt) | Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados | |
| BR112023000308A2 (pt) | Uso de taurolidina contra vírus | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| ES2312421T3 (es) | Composicion farmaceutica en gel. | |
| BR112022019486A2 (pt) | Agente terapêutico para infecção por coronavírus | |
| Arza | Upper and lower respiratory conditions | |
| BRPI0920492A2 (pt) | uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. | |
| Wang et al. | Tissue injury by hot fluid containing nitrogen mustard | |
| BR112018072164A2 (pt) | composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição | |
| BR112023021049A2 (pt) | Uso de adenina na fabricação de um medicamento para tratamento de úlcera diabética | |
| BR9916963A (pt) | Bupropiona para tratamento de doenças virais |